Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Highly constrained bicyclic VLA-4 antagonists.

Linda L Chang1, Quang Truong, George A Doss

  • 1Department of Medicinal Chemical Research, Merck Research Laboratories, Rahway, NJ 07065, USA.

Bioorganic & Medicinal Chemistry Letters
|November 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Supporting emotional preparedness in intensive care nurses: Embedding wellbeing through curriculum redesign.

Contemporary nurse·2025
Same author

Acute Immunological Phenotypes in Individuals with Traumatic Spinal Cord Injury.

Journal of neurotrauma·2025
Same author

Spinal Cord Transcutaneous Stimulation in Cervical Spinal Cord Injury: A Review Examining Upper Extremity Neuromotor Control, Recovery Mechanisms, and Future Directions.

Journal of neurotrauma·2024
Same author

Corticospinal inhibition investigated in relation to upper extremity motor function in cervical spinal cord injury.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2024
Same author

Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic.

Journal of medicinal chemistry·2024
Same author

Standing Reactive Postural Responses of Lower Limbs With and Without Self-Balance Assistance in Individuals With Spinal Cord Injury Receiving Epidural Stimulation.

Journal of neurotrauma·2023

Researchers explored cyclic beta-amino acids as VLA-4 antagonists for inflammatory diseases. Compound 5m, with a preferred dihedral angle, showed potent VLA-4 antagonism and good bioavailability.

Area of Science:

  • Immunology
  • Medicinal Chemistry
  • Pharmacology

Background:

  • Very late antigen-4 (VLA-4) plays a key role in inflammatory and autoimmune diseases.
  • Targeting VLA-4 is a therapeutic strategy for these conditions.

Purpose of the Study:

  • To investigate cyclic beta-amino acids (beta-aa) as potential VLA-4 antagonists.
  • To determine the structure-activity relationship, focusing on the dihedral angle (phi).

Main Methods:

  • Synthesis and evaluation of a series of cyclic beta-amino acids.
  • Measurement of binding affinity to VLA-4, specifically VCAM-Ig alpha4beta1.
  • Assessment of oral bioavailability in rats.

Main Results:

  • Binding affinity was strongly correlated with the dihedral angle (phi) of the beta-aa.

Related Experiment Videos

  • Compound 5m, featuring a bicyclic structure with an optimal phi of 120 degrees, demonstrated high VLA-4 antagonism (IC50 = 54 nM).
  • Compound 5m exhibited significant oral bioavailability in rats (F = 49%).

    • Conclusions:

    • Cyclic beta-amino acids can be designed as potent VLA-4 antagonists.
    • Optimizing the dihedral angle is crucial for high binding affinity.
    • Compound 5m represents a promising candidate for treating VLA-4-mediated diseases.